How many stocks are there of Aptinyx?
The current number of stocks of Aptinyx is 67.72 M undefined.
Aptinyx Stocks 2024
Aptinyx Stocks
67.72 M
Ticker
APTX
ISIN
US03836N1037
WKN
A2JPB1
In 2024, Aptinyx had 67.72 M outstanding stocks, a 0% change from the 67.72 M stocks in the previous year.
The Aptinyx Stocks history
| YEAR | NUMBER OF STOCKS (undefined USD) |
|---|---|
| 2028e | 67.72 |
| 2027e | 67.72 |
| 2026e | 67.72 |
| 2025e | 67.72 |
| 2024e | 67.72 |
| 2023e | 67.72 |
| 2022 | 67.72 |
| 2021 | 67.22 |
| 2020 | 48.87 |
| 2019 | 33.56 |
| 2018 | 33.34 |
| 2017 | 32.54 |
| 2016 | 32.54 |
Aptinyx shares outstanding US03836N1037 · A2JPB1
The number of shares was Aptinyx in 2023 — This indicates how many shares 67.72 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Aptinyx earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Aptinyx's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Aptinyx’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Aptinyx's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2016 | 32.54 M Aktien |
| 2017 | 32.54 M Aktien |
| 2018 | 33.34 M Aktien |
| 2019 | 33.56 M Aktien |
| 2020 | 48.87 M Aktien |
| 2021 | 67.22 M Aktien |
| 2022 | 67.72 M Aktien |
| 2023e | 67.72 M Aktien |
| 2024e | 67.72 M Aktien |
| 2025e | 67.72 M Aktien |
| 2026e | 67.72 M Aktien |
| 2027e | 67.72 M Aktien |
| 2028e | 67.72 M Aktien |
Aptinyx Aktienanalyse
What does Aptinyx do?
Aptinyx Inc is a biopharmaceutical company specializing in the development of therapies for the treatment of neurological diseases. The company was founded in 2015 in Evanston, Illinois, USA, and has since achieved an impressive track record in researching and developing innovative therapies. The history of Aptinyx Inc begins with a group of experienced scientists and researchers who came together to push the boundaries of neuroscience research and discover new treatment options for people with brain disorders. The company is based on the belief that the human brain is a fascinating and complex entity that still holds many secrets. The company is committed to improving human well-being through innovative neurotherapeutic products and services. Aptinyx Inc's business model focuses on the research, development, and commercialization of novel therapeutic treatments for neurological diseases. The company closely collaborates with leading academic institutions and facilities to leverage the best research findings and methods. The company has a strong scientific foundation led by an experienced team of researchers and developers working on innovative biomarker and therapy strategies. Aptinyx Inc has focused on the development of neuromodulators and neuroprotectants to treat neurological diseases, including pain disorders, peripheral neuropathies, neuropathic pain, Parkinson's disease, post-traumatic stress disorder (PTSD), and other central nervous system disorders. Aptinyx Inc's products are based on a comprehensive understanding of the fundamentals of the nervous system and how it functions. The company offers a variety of products and services, including novel therapeutics for the treatment of pain, neuropathy, and other neurological diseases. These products are based on the utilization of Aptinyx's proprietary technologies to selectively modulate specific cell types and signaling pathways in the nervous system. The products and services of Aptinyx Inc have been regulated by leading health authorities in the US and Europe. Aptinyx Inc has two main divisions of products: the first focus is on the development of neuromodulators that specifically alleviate pain and modulate the brain. The second focus is on the development of neuroprotectants that help protect neurons and reduce inflammation in the nervous system. These two divisions are closely interconnected as they are based on a common platform grounded in the exploration of novel biomarkers and therapeutic targets. The products of Aptinyx Inc are designed for both pain relief and improvement of neural functions. Additionally, these products aim to enhance patient experience and quality of life. The company consistently collaborates with potential partners and experts to develop products tailored to the needs of patients and healthcare providers. Overall, Aptinyx Inc has revolutionized the world of neuroscience by exploring and developing innovative solutions for neurological diseases. The company has achieved an impressive track record by utilizing its scientific expertise and groundbreaking technologies to set new trends in neuroscience research and therapeutics. In summary, Aptinyx Inc has developed a unique approach to the development of neuromodulators and neuroprotectants based on a deep understanding of the structure and function of the nervous system. The products and services of the company have the potential to play a significant role in improving the quality of life for patients with neurological diseases. Aptinyx ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Aptinyx's Shares Outstanding
Aptinyx's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Aptinyx’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Aptinyx’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Aptinyx’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Aptinyx stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Aptinyx are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Aptinyx evolved in recent years?
The number of shares of Aptinyx has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Aptinyx as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Aptinyx?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Aptinyx pay?
Over the past 12 months, Aptinyx paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aptinyx is expected to pay a dividend of 0 USD.
What is the dividend yield of Aptinyx?
The current dividend yield of Aptinyx is .
When does Aptinyx pay dividends?
Aptinyx pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Aptinyx?
Aptinyx paid dividends every year for the past 0 years.
What is the dividend of Aptinyx?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Aptinyx located?
Aptinyx is assigned to the 'Health' sector.
Wann musste ich die Aktien von Aptinyx kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Aptinyx from 12/29/2023 amounting to 0.099 USD, you needed to have the stock in your portfolio before the ex-date on 1/2/2024.
When did Aptinyx pay the last dividend?
The last dividend was paid out on 12/29/2023.
What was the dividend of Aptinyx in the year 2023?
In the year 2023, Aptinyx distributed 0 USD as dividends.
In which currency does Aptinyx pay out the dividend?
The dividends of Aptinyx are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Aptinyx
Our stock analysis for Aptinyx Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aptinyx Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
